The MAINSAIL trial: an expected failure
Mené sur 1 059 patients atteints d'un cancer métastatique de la prostate résistant à la castration, cet essai randomisé de phase III évalue l'efficacité, du point de vue de la survie globale, et la toxicité de l'ajout de lénalidomide à un traitement combinant docétaxel et prednisone
In The Lancet Oncology, Daniel Petrylak and colleagues report the final analysis of the MAINSAIL trial, which tested the value of lenalidomide (an analogue of thalidomide with antiproliferative, anti-angiogenic, and immunomodulatory properties) combined with standard docetaxel every 3 weeks plus prednisone in patients with castration-resistant prostate cancer. The lenalidomide regimen, which was expected to be substantially better than docetaxel and prednisone with placebo, proved inferior because it was associated with a significantly increased risk of progression and death, and worse toxic effects.
The Lancet Oncology , commentaire, 2014